Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis
Rens N, Groot C, Goldhaber-Fiebert J, Croda J, Andrews J. Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis. Clinical Infectious Diseases 2020, 71: 3136-3143. PMID: 31905381, PMCID: PMC7819527, DOI: 10.1093/cid/ciz1212.Peer-Reviewed Original ResearchMeSH KeywordsArylamine N-AcetyltransferaseBrazilCost-Benefit AnalysisHumansIndiaIsoniazidPharmacogeneticsQuality-Adjusted Life YearsSouth AfricaTuberculosisConceptsDrug-susceptible tuberculosisIncremental cost-effectiveness ratioSlow NAT2 acetylatorsWeight-based dosingOne-way sensitivity analysesCost-effectiveness ratioN-acetyltransferase 2 geneEffectiveness of drugsProbabilistic sensitivity analysesPotential clinical impactGeneXpert testActive tuberculosisNAT2 acetylatorsTreatment failurePharmacokinetic variabilityRapid acetylatorsTuberculosis treatmentClinical impactMAIN OUTCOMEPharmacogenomic testsHealth outcomesIsoniazid toxicityInterindividual variabilityPatientsTuberculosis